BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
March 15 2023 - 8:15AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company specializing in targeted immunotherapies for cancer, has
been selected to present four posters at the 2023 American
Association for Cancer Research (AACR) Annual Meeting held from
April 14 - 19, 2023 at Orange County Convention Center, Orlando,
Florida.
The available abstract titles and texts are
based on previously-disclosed patient data. However, the posters
presented at AACR will contain refreshed survival updates, new
patient data, and potential late-breaking discoveries.
Poster details include the following:
Poster 1:
Title: Whole cell antigen presenting immune
stimulating cells (Bria-IMT) for the treatment of metastatic breast
cancerSession Title: Phase II Clinical Trials
1Session Date and Time: Monday Apr 17, 2023 1:30
PM - 5:00 PMLocation: Poster Section
47Poster Board Number: 5Abstract
Presentation Number: CT143
Poster 2:
Title: Engineering semi-allogeneic whole cancer
vaccines with enhanced immunogenicity for the treatment of advanced
solid tumorsSession Category:
ImmunologySession Title: Oncolytic Viruses,
Anticancer Vaccines, and Other Immunomodulatory
TherapiesSession Date and Time: Sunday Apr 16,
2023 1:30 PM - 5:00 PMLocation: Poster Section
24Poster Board Number: 5Published Abstract
Number: 685
The following two posters will be presented in a
collaboration led by a team from Creatv MicroTech, Inc., an
oncology diagnostic company.
Poster 3:
Title: Tumor macrophage fusion cells detected
in the circulation of metastatic breast cancer patients is
prognostic for rapid progression and deathSession
Category: Clinical Research Excluding
TrialsSession Title: Liquid Biopsies:
Circulating Nucleic Acids and Circulating Tumor Cells
2Session Date and Time: Monday Apr 17, 2023
9:00 AM - 12:30 PMLocation: Poster Section
44Poster Board Number: 24Published
Abstract Number: 2310
Poster 4:
Title: Micronuclei in circulating stromal
cells correlates with PD-L1 expression and predicts progression in
metastatic breast cancerSession
Category: Molecular/Cellular Biology and
GeneticsSession Title: Targeting Replication
Stress and the Immune MicroenvironmentSession Date and
Time: Sunday Apr 16, 2023 1:30 PM - 5:00
PMLocation: Poster Section 11Poster
Board Number: 6Published Abstract
Number: 304
Following the presentations, copies of the
posters will be posted on
https://briacell.com/scientific-publications/.
The abstracts will be published in an
online-only Proceedings supplement to the AACR journal Cancer
Research on Friday, April 14, 2023.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Examples of
forward-looking statements in this news release include statements
about: (i) BriaCell's participation at the American Association for
Cancer Research (AACR) 2023 Annual Meeting; and (ii) the potential
content of posters presented at AACR with respect to refreshed
survival updates, new patient data, and potential late-breaking
discoveries. Forward-looking statements are based on BriaCell’s
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully under the heading
“Risks and Uncertainties” in the Company's most recent Management’s
Discussion and Analysis, under the heading “Risk Factors” in the
Company's most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2023 to Jul 2024